American Journal of Clinical and Experimental Medicine

Volume 10, Issue 2, March 2022

  • Focused Neuroregulation in the Treatment and Prevention of Mental and Physical Illness

    Michael Raymond Binder

    Issue: Volume 10, Issue 2, March 2022
    Pages: 49-58
    Received: 22 February 2022
    Accepted: 11 March 2022
    Published: 23 March 2022
    Abstract: Despite the enormous strides that have been made in neuroscience, the pathophysiology of psychiatric disorders remains unclear. Consequently, various forms of psychotherapy, pharmacotherapy, and neuromodulatory therapy continue to be applied without a clear understanding of what pathological process is being treated. However, an emerging hypothesis... Show More
  • Metformin Intolerance: A Proposal for Definition Using the GSRS

    Paul Bouter, Oscar Natan

    Issue: Volume 10, Issue 2, March 2022
    Pages: 59-62
    Received: 1 March 2022
    Accepted: 26 March 2022
    Published: 9 April 2022
    Abstract: Metformin is a first line drug for the treatment of patients with type 2 diabetes mellitus (T2DM) and has been associated with metformin intolerance with disappointing patient adherence. Since there is no official definition for metformin intolerance, comparison of international study results on gastrointestinal complaints is almost impossible. In ... Show More
  • The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin

    Wu Yuyan, Shan Tiantian, Pan Xiangtao

    Issue: Volume 10, Issue 2, March 2022
    Pages: 63-66
    Received: 9 April 2022
    Published: 14 April 2022
    Abstract: Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy voluntee... Show More